- Home
- ITGR vs VRDN Comparison
ITGR vs VRDN Comparison
Compare ITGR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITGR | VRDN |
|---|---|---|
| Founded | 1970 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | ITGR | VRDN |
|---|---|---|
| Price | $79.12 | $32.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $95.00 | $39.73 |
| AVG Volume (30 Days) | 648.7K | ★ 1.7M |
| Earning Date | 10-23-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $1,831,074,000.00 | $70,789,000.00 |
| Revenue This Year | $9.58 | $26,477.48 |
| Revenue Next Year | N/A | $6.23 |
| P/E Ratio | $32.41 | ★ N/A |
| Revenue Growth | 9.54 | ★ 23340.07 |
| 52 Week Low | $62.00 | $9.90 |
| 52 Week High | $146.36 | $34.04 |
Technical Indicators
Market Signals| Indicator | ITGR | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 67.62 | 60.60 |
| Support Level | $75.64 | $31.20 |
| Resistance Level | $80.95 | $33.52 |
| Average True Range (ATR) | 2.10 | 1.25 |
| MACD | 1.39 | -0.30 |
| Stochastic Oscillator | 84.53 | 51.76 |
Price Performance
Historical ComparisonAbout ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).